· Published by Health Canada · Official notice
This is duplicated text of a letter from Janssen Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
June 9, 2014
Subject: New safety information regarding the risk of anaphylaxis and Toxic Epidermal Necrolysis (TEN) associated with TERAZOL® 7 Vaginal Cream 0.4% (terconazole); TERAZOL® 3 Dual-Pak®- Vaginal Cream 0.8%/Vaginal Ovules 80 mg (terconazole)
Janssen Inc., in consultation with Health Canada, would like to inform you about important new safety information regarding the risk of serious allergic reactions associated with the use of TERAZOL®.
TERAZOL® 7 Vaginal Cream and TERAZOL® 3 Dual-Pak® Vaginal Cream/Vaginal Ovules are used for the treatment of yeast infections caused by an organism called Candida albicans.
Janssen Inc. has provided this information to doctors and pharmacists across Canada. Information regarding the risk of serious allergic reactions has been included in the consumer information document. For more information, patients should consult their healthcare professional.
Managing marketed health product-related side effects depends on healthcare professionals and consumers reporting them. Any case of anaphylaxis, TEN, or other serious or unexpected adverse reactions in patients receiving TERAZOL® 7 or TERAZOL® 3 Dual-Pak® should be reported to Janssen Inc. or Health Canada.
Drug Safety Department
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
Or call toll free at 1-866-825-7122
Or email to dsscan@joica.jnj.com
Or fax to 1-866-767-5865
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
original signed by
Cathy Lau, Ph.D.
Vice President
Regulatory Affairs and Quality Management